Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -90.79 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 23.23 | 7,823.26 | 33.69 | 0.00 |
| Quality | ||||
| ROIC | 2.65% | 0.01% | 3.28% | 0.00% |
| Gross Margin | 55.33% | 54.70% | 57.40% | 0.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -1.66% | 243.55% | 338.42% | 393.95% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.38 | -321.59 | -1.11 | 0.00 |
| Interest Coverage | 36.79 | 17.01 | 32.92 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.58 | 0.00 | 0.60 | 0.00 |
| Cash Conversion Cycle | 169.06 | 23,014.71 | 167.42 | 0.00 |